
Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using its gene-editing platform [2][3] - The company is pioneering an allogeneic approach for CAR T immunotherapies in oncology, offering off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [2][3] - Cellectis has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that control the entire cell and gene therapy value chain [2] Financial Reporting - Cellectis will report its financial results for the second quarter of 2025 on August 4, 2025, after the close of the US market [1] - An investor conference call and webcast will take place on August 5, 2025, at 8:00 AM ET, to discuss the second quarter results and provide updates on business activities [2] Contact Information - Media contacts include Pascalyne Wilson and Patricia Sosa Navarro for communications inquiries [4] - Investor relations inquiries can be directed to Arthur Stril, the Chief Financial Officer & Chief Business Officer [4]